1,3- benzothiazol- 2- yl(2- ((2- (3- pyridinyl)ethyl)amino)- 4- pyrimidinyl)acetonitrile

a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective activity; also an NSAID

Also Known As:

1,3-benzothiazol-2-yl(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile (bis(trifluoroacetate)); AS 601245; AS-601245; AS601245

Networked: 6 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barrera, Giuseppina: 2 articles (01/2012 - 01/2012)
2.	Cerbone, Angelo: 2 articles (01/2012 - 01/2012)
3.	Ciamporcero, Eric: 2 articles (01/2012 - 01/2012)
4.	Dianzani, Chiara: 2 articles (01/2012 - 01/2012)
5.	Dianzani, Mario Umberto: 2 articles (01/2012 - 01/2012)
6.	Ferretti, Carlo: 2 articles (01/2012 - 01/2012)
7.	Minelli, Rosalba: 2 articles (01/2012 - 01/2012)
8.	Pettazzoni, Piergiorgio: 2 articles (01/2012 - 01/2012)
9.	Pizzimenti, Stefania: 2 articles (01/2012 - 01/2012)
10.	Roma, Guglielmo: 2 articles (01/2012 - 01/2012)

Related Diseases

1.	Gliosis 01/01/2008 - "The present results suggest that AS601245 reduced damage to neurites and decreased astrogliosis following global ischaemia and also improved long-term memory, supporting JNK inhibition as a promising therapeutic strategy for ischaemic insults to the CNS."
2.	Myocardial Ischemia (Ischemic Heart Diseases) 07/01/2004 - "2 This study investigates the effects of AS601245, a nonpeptide ATP competitive JNK inhibitor, on infarct size caused by myocardial ischemia/reperfusion in anaesthetized rats. "
3.	Infarction (Infarctions) 07/01/2004 - "3 AS601245 significantly reduced infarct size at 4.5 mg kg(-1) (-44%; P<0.001) and 15 mg kg(-1) i.v. (-40.3%; P<0.001) similarly to 3-aminobenzamide (-44.2%; P<0.001). " 07/01/2004 - "2 This study investigates the effects of AS601245, a nonpeptide ATP competitive JNK inhibitor, on infarct size caused by myocardial ischemia/reperfusion in anaesthetized rats. "
4.	Brain Ischemia (Cerebral Ischemia) 07/01/2004 - "In the current study, we report that a small molecule, AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile), which has been shown to inhibit the JNK signaling pathway, promotes cell survival after cerebral ischemia. "
5.	Colonic Neoplasms (Colon Cancer) 01/01/2012 - "Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells." 01/01/2012 - "We analysed the effects of AS601245 (a JNK inhibitor) and clofibrate alone or in association, on proliferation, apoptosis, differentiation and the gene expression profile of CaCo-2 human colon cancer cells. " 01/01/2012 - "AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells." 01/01/2012 - "We analysed the effects of rosiglitazone (PPARγ ligand) and AS601245 (a selective JNK inhibitor) alone or in association on adhesion and migration of CaCo-2, HT29, and SW480 human colon cancer cells and investigated, through microarray analysis, the genes involved in these processes. "

Related Drugs and Biologics

1.	Adenosine Triphosphate (ATP)
2.	acetonitrile
3.	Ligands
4.	Clofibrate
5.	Rosiglitazone (Avandia)
6.	Etanercept (Enbrel)
7.	3-aminobenzamide